Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
satraplatin + paclitaxel
- Development stage
- Phase 2
- Lead developer
- GPC Biotech
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Satraplatin + paclitaxel is a combination of two chemotherapeutic agents investigated primarily for the treatment of advanced cancers, including prostate and non-small cell lung cancer. Satraplatin is an orally bioavailable platinum-based compound (code name JM216) that acts as a DNA antagonist by forming DNA adducts and crosslinks, thereby inhibiting DNA replication and transcription, leading to cell cycle arrest and apoptosis. It is notable for its oral administration route, unlike other platinum analogues which require intravenous infusion[2][5][6]. Paclitaxel (brand name Taxol) is a microtubule inhibitor that prevents cancer cells from dividing by stabilizing microtubules and blocking mitosis[7]. Preclinical studies have shown synergistic antitumor activity when these drugs are used in combination, particularly in prostate cancer models[8]. The combination has been evaluated in clinical trials for advanced non-small cell lung cancer and hormone-refractory prostate cancer[3][4].
- Brand names
- SPERA
- Other names
- SatraPlatin Expanded Rapid AccessTaxol
02
Targets
DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on satraplatin + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on satraplatin + paclitaxel.